How does 531015's PE Ratio compare to its peers?

531015 is expensive based on its Price-To-Earnings Ratio (92.8x) compared to the peer average (27.5x).

How does 531015's PE Ratio compare vs other companies in the IN IT Industry?

531015 is expensive based on its Price-To-Earnings Ratio (92.8x) compared to the Indian IT industry average (38.2x).

What is 531015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 531015's Price-To-Earnings Fair Ratio for valuation analysis.

What is the Fair Price of 531015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

531015 (₹10.15) is trading above our estimate of [[fair value]] (₹0.06)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

531015 Stock Overview

Engages in the IT and ITES services business. More details

531015 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Debt is not well covered by operating cash flow

Negative shareholders equity

Shares are highly illiquid

Makes less than USD$1m in revenue (₹1M)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Venmax Drugs and Pharmaceuticals Limited Competitors

Asya Infosoft

BSE:511144

₹43.5m

Shyama Computronics and Services

BSE:531219

₹60.9m

Wherrelz IT Solutions

BSE:543436

₹98.8m

Euphoria Infotech (India)

BSE:544094

₹171.5m

Price History & Performance

Summary of share price highs, lows and changes for Venmax Drugs and Pharmaceuticals
Historical stock prices
Current Share Price	₹10.15
52 Week High	₹10.15
52 Week Low	₹6.27
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-17.21%

Recent updates

Shareholder Returns

	531015	IN IT	IN Market
7D	27.2%	-0.3%	-0.9%
1Y	n/a	22.1%	22.5%

Return vs Industry: Insufficient data to determine how 531015 performed against the Indian IT industry.

Return vs Market: Insufficient data to determine how 531015 performed against the Indian Market.

Price Volatility

Is 531015's price volatile compared to industry and market?
531015 volatility
531015 Average Weekly Movement	n/a
IT Industry Average Movement	6.4%
Market Average Movement	6.2%
10% most volatile stocks in IN Market	9.1%
10% least volatile stocks in IN Market	4.1%

Stable Share Price: 531015's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine 531015's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1988	n/a	Nooka Krishnaiah	www.venmaxdrugs.com

Venmax Drugs and Pharmaceuticals Limited engages in the IT and ITES services business. The company was formerly known as Yenkey Drugs & Pharmaceuticals Ltd and changed its name to Venmax Drugs and Pharmaceuticals Limited in April 2009. Venmax Drugs and Pharmaceuticals Limited was incorporated in 1988 and is based in Hyderabad, India.

Venmax Drugs and Pharmaceuticals Limited Fundamentals Summary

How do Venmax Drugs and Pharmaceuticals's earnings and revenue compare to its market cap?
531015 fundamental statistics
Market cap	₹53.18m
Earnings (TTM)	₹573.00k
Revenue (TTM)	₹1.04m

92.8x

P/E Ratio

51.1x

P/S Ratio

Is 531015 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
531015 income statement (TTM)
Revenue	₹1.04m
Cost of Revenue	₹1.12m
Gross Profit	-₹82.00k
Other Expenses	-₹655.00k
Earnings	₹573.00k

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	-7.88%
Net Profit Margin	55.10%
Debt/Equity Ratio	-55.1%

How did 531015 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/17 04:04
End of Day Share Price	2024/12/17 00:00
Earnings	2024/06/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Venmax Drugs and Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Venmax Drugs and Pharmaceuticals BSE:531015 Stock Report